Abstract:Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive group of breast cancers. The lack of specific actionable targets makes chemotherapy the main treatment for TNBC patients. However, chemotherapy has limited success due to scarce bioavailability, severe systemic side effects and drug resistance. Polymeric nanoparticles (PNPs) may efficiently deliver in vivo therapeutics to tumors when conjugated to specific targeting agents. Potential agents for targeting tumor cells are aptamers: short, single-stranded oligonucleotides that interact at high affinity with their targets. Here, we report the characterization of new multifunctional nanovectors consisting of safe and biodegradable PNPs, highly specific TNBC aptamers as delivery agents and artificial small interfering RNA (siRNA) as drug payload, designed to suppress programmed cell death-ligand 1 (PD-L1) expression, a major feature of immune evasion in cancer cells. We efficiently entrapped siRNA-PD-L1 into PNPs. To enable active targeting, siPD-L1-PNPs were functionalized with TN145-aptamer, which we previously generated by cell-SELEX and shown to bind with nanomolar affinity to TNBC cells distinguishing them from both normal breast cells and non-TNBC breast cancer cells. TN145 aptamer actively internalizes into target cells, thus representing a good candidate to deliver a therapeutic payload. We show that the aptamer-decorated nanovectors efficiently deliver fluorescein-labeled siRNA into TNBC MDA-MB-231 and BT-549 cells, as assessed by confocal microscopy. Unconjugated nanovectors or conjugated with scrambled aptamers were used as controls. Non-TNBC BT-474 and MCF7 breast cancer cells, were used to exclude unspecific binding. Importantly, a 30-min incubation of TN145-conjugated nanovectors on target cells, at a siPD-L1 concentration of 1 nM, results in stronger PD-L1 silencing than that achieved by siPD-L1 delivered via a commercial transfection reagent. Furthermore, TN145-PNPs loaded with both siPD-L1 and cisplatin were generated and the efficacy of combined treatment was tested on tumor cells and tumor and immune cell co-cultures. Chemotherapy, including cisplatin, has been reported to induce PD-L1 enrichment in TNBC cells, hence an aptamer-targeted nanosystem enabling the synergistic effect of siRNA that directly knocks down PD-L1 expression on tumor cells with a powerful chemotherapeutic drug could be the future way to eradicate TNBC cells. Citation Format: Lisa Agnello, Simona Camorani, Silvia Tortorella, Annachiara d'Argenio, Roberto Nilo, Monica Fedele, Antonella Zannetti, Mauro Comes Franchini, Laura Cerchia. Nano-immunotherapy in TNBC: Aptamer-based nanoparticles for PD-L1 siRNA delivery to cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 367.

Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis

Abstract 367: Nano-immunotherapy in TNBC: Aptamer-based nanoparticles for PD-L1 siRNA delivery to cancer cells

Treating Metastatic Triple Negative Breast Cancer with CD44/neuropilin Dual Molecular Targets of Multifunctional Nanoparticles.

Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy

Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment

Efficient TNBC immunotherapy by dual reprogramming tumor-infiltrating dendritic cells and tumor-associated macrophages with stimulus-responsive miR155 nanocomplexes

Dendritic polylysine co-delivery of paclitaxel and siAXL enhances the sensitivity of triple-negative breast cancer chemotherapy

Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody

Drug Self‐Delivery Nanocubes Enhance O2‐Economized Photodynamic‐Immunotherapy of Triple‐Negative Breast Cancer by Downregulating Wnt/β‐catenin Signaling

PD‐L1 Antibody‐Conjugated PAMAM Dendrimer Nanosystem for Simultaneously Inhibiting Glycolysis and Promoting Immune Response in Fighting Breast Cancer

A Dual‐Targeting Liposome Enhances Triple‐Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation

Transformable self-delivered supramolecular nanomaterials combined with anti-PD-1 antibodies alleviate tumor immunosuppression to treat breast cancer with bone metastasis

JQ1-Loaded Polydopamine Nanoplatform Inhibits C-Myc/programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.

A dual-sensitive nanoparticle-mediated deepening synergistic therapy strategy involving DNA damage and ICD stimuli to treat triple-negative breast cancer

Multifunctional Nanoplatform-Mediated Chemo-Photothermal Therapy Combines Immunogenic Cell Death with Checkpoint Blockade to Combat Triple-Negative Breast Cancer and Distant Metastasis

Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy

Augmentation of antitumor function of tumor-infiltrating lymphocytes against triple-negative breast cancer by PD-1 blockade

Dual-blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle.

Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer

Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer